206 related articles for article (PubMed ID: 38239353)
1. Role of MCP-1 as an inflammatory biomarker in nephropathy.
Liu Y; Xu K; Xiang Y; Ma B; Li H; Li Y; Shi Y; Li S; Bai Y
Front Immunol; 2023; 14():1303076. PubMed ID: 38239353
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in patients with biopsy-proved diabetic nephropathy compared to isolated lupus or crescentic glomerulonephritis.
Chou YH; Lin WC; Chen YM
Diabetes Res Clin Pract; 2019 Feb; 148():144-151. PubMed ID: 30641169
[TBL] [Abstract][Full Text] [Related]
3. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis.
Noris M; Bernasconi S; Casiraghi F; Sozzani S; Gotti E; Remuzzi G; Mantovani A
Lab Invest; 1995 Dec; 73(6):804-9. PubMed ID: 8558841
[TBL] [Abstract][Full Text] [Related]
4. Effect of retinoic acid in experimental diabetic nephropathy.
Han SY; So GA; Jee YH; Han KH; Kang YS; Kim HK; Kang SW; Han DS; Han JY; Cha DR
Immunol Cell Biol; 2004 Dec; 82(6):568-76. PubMed ID: 15550114
[TBL] [Abstract][Full Text] [Related]
5. Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis.
Dai C; Liu Z; Zhou H; Li L
Chin Med J (Engl); 2001 Aug; 114(8):864-8. PubMed ID: 11780369
[TBL] [Abstract][Full Text] [Related]
6. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice.
Zoja C; Liu XH; Donadelli R; Abbate M; Testa D; Corna D; Taraboletti G; Vecchi A; Dong QG; Rollins BJ; Bertani T; Remuzzi G
J Am Soc Nephrol; 1997 May; 8(5):720-9. PubMed ID: 9176841
[TBL] [Abstract][Full Text] [Related]
7. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.
Tesch GH
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F697-701. PubMed ID: 18272603
[TBL] [Abstract][Full Text] [Related]
8. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis.
Wada T; Furuichi K; Segawa-Takaeda C; Shimizu M; Sakai N; Takeda SI; Takasawa K; Kida H; Kobayashi KI; Mukaida N; Ohmoto Y; Matsushima K; Yokoyama H
Kidney Int; 1999 Sep; 56(3):995-1003. PubMed ID: 10469367
[TBL] [Abstract][Full Text] [Related]
9. Urinary fractalkine and monocyte chemoattractant protein-1 as possible predictors of disease activity of childhood glomerulonephritis.
Aizawa T; Imaizumi T; Tsuruga K; Watanabe S; Yoshida H; Kumagai N; Ito E; Tanaka H
Tohoku J Exp Med; 2013 Dec; 231(4):265-70. PubMed ID: 24284376
[TBL] [Abstract][Full Text] [Related]
10. Monocyte chemoattractant protein-1 and the kidney.
Haller H; Bertram A; Nadrowitz F; Menne J
Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):42-9. PubMed ID: 26625862
[TBL] [Abstract][Full Text] [Related]
11. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases.
Morii T; Fujita H; Narita T; Koshimura J; Shimotomai T; Fujishima H; Yoshioka N; Imai H; Kakei M; Ito S
Ren Fail; 2003 May; 25(3):439-44. PubMed ID: 12803507
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
Devarapu SK; Kumar Vr S; Rupanagudi KV; Kulkarni OP; Eulberg D; Klussmann S; Anders HJ
Clin Immunol; 2016 Aug; 169():139-147. PubMed ID: 27392463
[TBL] [Abstract][Full Text] [Related]
13. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.
Chow FY; Nikolic-Paterson DJ; Ozols E; Atkins RC; Rollin BJ; Tesch GH
Kidney Int; 2006 Jan; 69(1):73-80. PubMed ID: 16374426
[TBL] [Abstract][Full Text] [Related]
14. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis.
Marks SD; Williams SJ; Tullus K; Sebire NJ
Nephrol Dial Transplant; 2008 Nov; 23(11):3521-6. PubMed ID: 18495743
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy.
Wada T; Furuichi K; Sakai N; Iwata Y; Yoshimoto K; Shimizu M; Takeda SI; Takasawa K; Yoshimura M; Kida H; Kobayashi KI; Mukaida N; Naito T; Matsushima K; Yokoyama H
Kidney Int; 2000 Oct; 58(4):1492-9. PubMed ID: 11012884
[TBL] [Abstract][Full Text] [Related]
16. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis.
Lloyd CM; Minto AW; Dorf ME; Proudfoot A; Wells TN; Salant DJ; Gutierrez-Ramos JC
J Exp Med; 1997 Apr; 185(7):1371-80. PubMed ID: 9104823
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.
Gupta R; Yadav A; Aggarwal A
Clin Rheumatol; 2016 Nov; 35(11):2707-2714. PubMed ID: 27624649
[TBL] [Abstract][Full Text] [Related]
18. Glomerular expression of C-C chemokines in different types of human crescentic glomerulonephritis.
Liu ZH; Chen SF; Zhou H; Chen HP; Li LS
Nephrol Dial Transplant; 2003 Aug; 18(8):1526-34. PubMed ID: 12897090
[TBL] [Abstract][Full Text] [Related]
19. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.
Tarabra E; Giunti S; Barutta F; Salvidio G; Burt D; Deferrari G; Gambino R; Vergola D; Pinach S; Perin PC; Camussi G; Gruden G
Diabetes; 2009 Sep; 58(9):2109-18. PubMed ID: 19587356
[TBL] [Abstract][Full Text] [Related]
20. PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.
Zhai JX; Zhang ZX; Feng YJ; Ding SS; Wang XH; Zou LW; Ye DQ
Mol Biol Rep; 2012 Jun; 39(6):6763-71. PubMed ID: 22318546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
